For the Media
Dr. Stephanie Lee is a member of Fred Hutch's Clinical Research Division and was recently elected to be the vice president of the American Society of Hematology (ASH), the world's larget professional society of hematologists. Her research is focused on hematopoietic cell transplantation and chronic-versus-host disease (GVHD) with an emphasis on survivorship challenges, quality of life and the impact of GVHD on patients who have undergone a transplant. Lee is also a transplant physician and treats patients at the Seattle Cancer Care Alliance, Hutch's clinical care partner.
Overview of Stephanie Lee Research/Clinical Focus
His overall research focus is cancer immunology and clinical expertise is treating patients with blood cancers.
The overall focus is survivorship challenges and quality of life after hematopoietic cell transplant (HCT) and chronic graft-versus-host disease (GVHD).
Featured Researcher Profile
Read more about Stephanie Lee's experiences as a transplant physician-scientist.
Clinical Research Division
Researchers conduct laboratory and patient-oriented research to better understand the mechanisms that drive cancer and other human diseases. Integrating a variety of disciplines, our investigators are continually developing new therapeutic approaches and leading clinical trials that help move discoveries from laboratory to patient. Our pioneering research has saved hundreds of thousands of lives.
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.